TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2188794
Drug: Eicosapentaenoic acid-rich
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid-rich fish oil (MaxEPA', 2.8 g EPA daily)
Study: 7003448
Drug: 0.96 g
Normalized name: TRIHEPTANOIN 0.96 g in 1 mL ORAL LIQUID [DOJOLVI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.96 g single oral dose of co-trimoxazole
Study: 7003448
Drug: 1.92 g
Normalized name: STARCH, CORN 31.92 g in 100 g TOPICAL PATCH [Legere Lavendar Foot Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.92 g single oral dose of co-trimoxazole
Study: 7003448
Drug: 2.88 g
Normalized name: ALCOHOL 2.16 g in 2.88 g / BENZALKONIUM CHLORIDE 0.003 g in 2.88 g TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.88 g single oral dose of co-trimoxazole
Study: 27298538
Drug: Sub-mucosal injection
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-mucosal injection of 0.5 mg/kg ketamine hydrochloride
Study: 24632042
Drug: EG 500
Normalized name: Prosys Leg 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG 500 (500 mg of encapsulated C. xanthocarpa)
Study: 24632042
Drug: EG 1000
Normalized name: BAG,LEG 1000ML CARDINAL #ZRLB1000H
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG 1000 (1000 mg of encapsulated C. xanthocarpa)
Study: 24632042
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG, placebo treatment)
Study: 15155114
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 microg subcutaneous daily)
Study: 11369904
Drug: BCX-34 dermal
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCX-34 dermal cream 1%
Study: 8214490
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (0.027 mg)
Study: 8214490
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (0.027 mg)
Study: 28124444
Drug: Cognitive-behavioral intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral intervention (CBT) combined with treatment-as-usual (TAU), weekly sessions for 3 months
Study: 22452928
Drug: Wood smoke
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood smoke exposure (14, 220, or 354 μg/m3 for 3 hours)
Study: 16223392
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 2 ml with epinephrine (5 microg/ml)
Study: 16223392
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine 4 ml with epinephrine (2.5 microg/ml)
Study: 16223392
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine 4 ml with epinephrine (5 microg/ml)
Study: 16223392
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine 4 ml (no epinephrine)
Study: 12139219
Drug: Dengue tetravalent
Normalized name: DENGUE TETRAVALENT VACCINE,LIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue tetravalent live-attenuated vaccine (two doses, given six months apart)
Study: 10557952
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral prednisone
Study: 8824656
Drug: 5‐ASA 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA 1.5 g b.d.
Study: 2285294
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cephradine every 12 h for 7 days
Study: 2285294
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg of amoxicillin‐clavulanate every 8 h for 7 days
Study: 7041936
Drug: Buprenorphine 1
Normalized name: buprenorphine 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 1 mg + Paracetamol 1000 mg
Study: 7041936
Drug: Buprenorphine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 1.5 mg + Paracetamol 1000 mg
Study: 7041936
Drug: Buprenorphine 2
Normalized name: buprenorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 2 mg + Paracetamol 1000 mg
Study: 28291545
Drug: Bevacizumab (B)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (B) + single agent chemotherapy (CT)
Study: 28291545
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent chemotherapy (CT)
Study: 25565364
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of 0.5 mg dutasteride and 0.4 mg tamsulosin
Study: 25565364
Drug: Watchful waiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watchful waiting with protocol-defined initiation of tamsulosin therapy if symptoms did not improve (WW-All)
Study: 21775681
Drug: Rituximab (anti-CD20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (anti-CD20 monoclonal antibody), administered as four weekly doses.
Study: 11433853
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean dose, 8.6 mg)
Study: 11433853
Drug: Midazolam plus
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam plus additional midazolam as needed (mean total dose, 12.2 mg)
Study: 11433853
Drug: Fentanyl (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1.4 micrograms/kg) plus midazolam (mean dose, 5.7 mg)
Study: 11433853
Drug: Fentanyl (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1.4 micrograms/kg), midazolam (mean dose, 5.8 mg) and methohexital as needed (mean dose, 61.0 mg)
Study: 9425919
Drug: Percutaneous acetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous acetic acid injection (50% acetic acid)
Study: 9425919
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (absolute ethanol)
Study: 31904855
Drug: IVIG (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (0.4 g/kg/d) for five consecutive days
Study: 24739906
Drug: Combination mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination mouth rinse (0.03% triclosan, 0.05% sodium fluoride, and 5% xylitol)
Study: 15359583
Drug: 2, 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2, 5, 10, or 25 mg tadalafil
Study: 11938824
Drug: Defibrase injection
DrugBank: Batroxobin (DB09005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrase injection (DI)
Study: 11938824
Drug: Acanthopanax injection
Normalized name: Manyprickle Acanthopanax
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acanthopanax injection (AI)
Study: 11938824
Drug: Ginaton injection
Normalized name: Genaton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginaton injection (GI)
Study: 1389316
Drug: Immunoglobulin (Endobulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin (Endobulin, Immuno) administered intravenously at a dose of 100 mg/kg/week during the first 3 months, followed by 2 x 200 mg/kg/month during the 4th, 5th, and 6th months
Study: 1389316
Drug: No immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunoglobulin administered
Study: 30732583
Drug: Comprehensive interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive interventions focused on treatment intensification and adherence improvement.
Study: 27443526
Drug: Extra Virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra Virgin Olive Oil (EVOO), 50 ml daily for 3 weeks
Study: 27443526
Drug: Refined Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined Olive Oil (ROO), 50 ml daily for 3 weeks
Study: 27002934
Drug: Intravenous rucaparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rucaparib (intermittent dosing schedule)
Study: 27002934
Drug: Oral rucaparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rucaparib (across all six dose levels)
Study: 22868016
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/kg (maximum of 8 mg)
Study: 14961167
Drug: MDK-group (supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDK-group (supplement with minerals and vitamin D plus vitamin K1)
Study: 14961167
Drug: MD-group (supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-group (supplement with minerals and vitamin D)
Study: 9627208
Drug: Anticonvulsant monotherapy
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant monotherapy (200mg CBZ, 500mg VPA, 100mg PHT)
Study: 6614422
Drug: Buprenorphine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (both doses)
Study: 3115662
Drug: Inhaled carbon
Normalized name: carbon dioxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled carbon dioxide (CO2) at constant flow into a breathing circuit
Study: 3115662
Drug: Inhaled carbon
Normalized name: carbon dioxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled carbon dioxide (CO2) during exercise
Study: 27225736
Drug: Balneotherapy (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy (21 sessions of spa treatment with 34.8 °C thermomineral water, 5 days a week)
Study: 24152852
Drug: K‐712 (phytonutrient),
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐712 (phytonutrient), 1 tab twice a day for one week/month
Study: 24152852
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg orally once a week
Study: 17187094
Drug: Bone tissue
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone tissue preserved in 98% glycerol solution at room temperature
Study: 17187094
Drug: Microbiological analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiological analysis of 98% glycerol solution and bone fragments
Study: 11865133
Drug: Entacapone treatment
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entacapone treatment for 2 months
Study: 2194280
Drug: Captopril treatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril treatment for 9 days in 15 patients with diabetic nephropathy
Study: 2194280
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment for 8 weeks in 40 patients with diabetic nephropathy
Study: 2194280
Drug: Metoprolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol treatment for 8 weeks in 40 patients with diabetic nephropathy
Study: 2194280
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with captopril in patients with diabetic nephropathy
Study: 2194280
Drug: Furosemide treatment
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide treatment adjusted for blood-pressure control in both groups
Study: 318049
Drug: Periocular injection
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular injection of penicillin combined with multiple preoperative applications of topical chloramphenicol‐sulphadimidine
Study: 318049
Drug: Topical chloramphenicol‐sulphadimidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chloramphenicol‐sulphadimidine
Study: 23998556
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment regime
Study: 24442560
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg once daily
Study: 30668332
Drug: Wu chu
Normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wu chu yu tang (WCYT) 3.0 g three times per day for 4 weeks
Study: 30668332
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once per day and WCYT placebo (3.0 g) three times per day for 4 weeks
Study: 23245537
Drug: Sertraline or
Normalized name: sertraline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline or Bupropion for 8 weeks
Study: 20812339
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (no treatment)
Study: 19460102
Drug: L-NAME (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (180 microg kg(−1)h(−1))
Study: 17310385
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg/day)
Study: 2878034
Drug: Intra-operative parenteral
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative parenteral gentamicin and vancomycin (with streptomycin in the irrigating solution)
Study: 30845949
Drug: Health Integrator
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Integrator with monthly health coaching sessions
Study: 25803348
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids combined with antibiotics
Study: 25803348
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids as monotherapy
Study: 22139679
Drug: Celecoxib (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (selective COX-2 inhibitor)
Study: 8126257
Drug: Ibuprofen 2400
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 2400 mg/day
Study: 1556674
Drug: Ibuprofen (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (both doses)
Study: 3432173
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride (90 mg/day)
Study: 28990651
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIT) - three exercise sessions per week for 4 weeks, with weekly maintenance sessions if surgery was delayed.
Study: 27267105
Drug: Pomalidomide plus
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide plus low-dose dexamethasone (POM + LoDEX)
Study: 23316791
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment plus whole body vibration (WBV) during supervised physical therapy
Study: 23316791
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment (control group)
Study: 23316791
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment plus WBV
Study: 21644804
Drug: Conjoint treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint treatment
Study: 21644804
Drug: Choice of
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of treatment modality
Study: 15787815
Drug: Spironolactone 200
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 200 mg daily
Study: 1606994
Drug: Digoxin 0.5
Normalized name: digoxin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.5 to 1 mg.d‐1 p.o. for 6 days
Study: 31560372
Drug: Oral Lefamulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Lefamulin (600 mg every 12 hours for 5 days)
Study: 31560372
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg every 24 hours for 7 days)
Study: 31560372
Drug: Oral Lefamulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Lefamulin
Study: 21537360
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral treatment (ICBT)
Study: 12520749
Drug: NP regimen
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP regimen (vinorelbine + cisplatin); vinorelbine: 25 mg/m2 on days 1 and 8, cisplatin: 35 mg/m2 on days 1-3
Study: 12520749
Drug: MVP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVP regimen (mitomycin + vindesine + cisplatin); mitomycin: 6 mg/m2 on day 1, vindesine: 3 mg/m2 on days 1 and 8, cisplatin: 30 mg/m2 on days 1-3
Study: 7897422
Drug: 240 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg/day ginkgolide B
Study: 7897422
Drug: 360 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg/day ginkgolide B
Study: 26446653
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid only (Control)
Study: 22869103
Drug: Acyclovir (twice-daily)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (twice-daily)
Study: 19838489
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (Camellia sinensis) 250 mg capsules
Study: 17309331
Drug: G17DT in
Normalized name: G17DT
DrugBank: G17DT Immunogen (DB04914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G17DT in combination with gemcitabine
Study: 18509176
Drug: Docetaxel therapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel therapy
Study: 11340898
Drug: Three-drug regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimens including docetaxel
Study: 10036460
Drug: Nursing practice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing practice model based on Aristotelian theory and Rogers' science; specific dosage and duration not mentioned.
Study: 30018942
Drug: Pulsed therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed therapeutic ultrasound (PUS) administered 2 times weekly for 6 weeks
Study: 30018942
Drug: Kneading massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kneading massage (KM) administered 2 times weekly for 6 weeks
Study: 18426851
Drug: Intratracheal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours
Study: 18426851
Drug: Surfactant only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant only (100 mg/kg of survanta), every 8 hours
Study: 16490736
Drug: Surgery +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery + chemotherapy (cisplatin 80 mg/m² on Day 1 and 5-fluorouracil 500 mg/m²/day on Days 1-5)
Study: 9350066
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pamidronate
Study: 9350066
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg pamidronate
Study: 2722900
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg twice daily for 3 days
Study: 30351511
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone 1250 mg/day for 3 days
Study: 30351511
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone 625 mg/day for 3 days
Study: 28598202
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of amlodipine administered in the evening
Study: 28598202
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of amlodipine administered in the morning
Study: 21609410
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (5 mg daily)
Study: 16871477
Drug: Tizanidine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (0.05 mg/kg/day)
Study: 15027185
Drug: BCG-PSN local
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-PSN local injection following CO2 laser resection
Study: 15027185
Drug: Interferon subcutaneous
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon subcutaneous injection following CO2 laser resection
Study: 11576768
Drug: Rifampicin (RIF)
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin (RIF) 450 mg capsule
Study: 11576768
Drug: Rifampicin‐isoniazid (RIF‐INH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin‐isoniazid (RIF‐INH) 450+300 mg FDC capsule
Study: 2030925
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of enteric coated (EC) pancreatic enzymes (patient's usual dose)
Study: 2030925
Drug: Small doses
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small doses of enteric coated (EC) pancreatic enzymes (1/4 usual dose)
Study: 7093115
Drug: Single morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single morning dose of methyldopa
Study: 7093115
Drug: Single evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single evening dose of methyldopa
Study: 10449266
Drug: Intravaginal 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 5-fluorouracil (5-FU) cream
Study: 10449266
Drug: Intravaginal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal placebo cream
Study: 2468964
Drug: N-acetylcysteine (NAC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC, 2,400 mg X 2) + isosorbide-5-mononitrate (5-ISMN, 60 mg)
Study: 2468964
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + isosorbide-5-mononitrate (5-ISMN, 60 mg)